Buy Lenvaxen 4 MG And 10 MG (Lenvatinib) - Mediaid pharmacy
Buy Lenvaxen 4 MG And 10 MG (Lenvatinib) - Mediaid pharmacy Online
Buy Lenvaxen 4 MG And 10 MG (Lenvatinib) - Mediaid pharmacy Bangladesh

Lenvaxen 4 MG And 10 MG (Lenvatinib)

Product Name : Lenvaxen
Generic Name : Lenvatinib
Formulation : Capsule
Available Pack Size : 30’s
Available Strengths : 4 mg and 10 mg
Registrations : Export Only

Message Us on WhatsApp

Product Information

Lenvaxen 4 MG and 10 MG (Lenvatinib) is an oral multi-kinase inhibitor supplied as 4 mg and 10 mg capsules in a 30’s pack under an Export Only registration. Its active ingredient, lenvatinib, simultaneously blocks vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1–4), and additional oncogenic kinases including PDGFRα, RET, and KIT, cutting off the tumor blood supply and suppressing tumor cell proliferation. Lenvaxen 4 MG and 10 MG Lenvatinib is approved for adults with radioiodine-refractory differentiated thyroid cancer (DTC), unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC) in combination with everolimus, and advanced endometrial carcinoma in combination with pembrolizumab. Because lenvatinib is a targeted oncology therapy, treating oncologists monitor patients for hypertension, hepatotoxicity, proteinuria, and cardiac events throughout treatment, and Mediaid Pharmacy supplies Lenvaxen 4 MG and 10 MG Lenvatinib alongside its wider oncology medicines portfolio and ships it worldwide to licensed importers, hospitals, and distributors.

Basic Product Information of Lenvaxen 4 MG and 10 MG (Lenvatinib)

Brand Name Lenvaxen 4 MG and 10 MG (Lenvatinib)
Product Name Lenvaxen
Generic Name Lenvatinib
Drug Class Multi-kinase Inhibitor, Receptor Tyrosine Kinase (RTK) Inhibitor, Antineoplastic Agent
Formulation Capsule
Available Strengths 4 mg and 10 mg
Available Pack Size 30’s (30 capsules per pack)
Primary Indication Radioiodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma (first-line), advanced renal cell carcinoma (with everolimus), and advanced endometrial carcinoma (with pembrolizumab) in adults
Registrations Export Only
Originator Reference Brand Lenvima (lenvatinib) by Eisai / Merck
Global Supplier Mediaid Pharmacy, Worldwide Shipping Available
Storage Conditions Store in a dry place away from light and moisture, at the temperature printed on the pack. Keep out of the reach of children.

How Lenvaxen 4 MG and 10 MG (Lenvatinib) Works: Multi-Kinase Inhibition Mechanism

Lenvatinib, the active ingredient in Lenvaxen 4 MG and 10 MG, is an oral receptor tyrosine kinase (RTK) inhibitor that simultaneously blocks VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4) the primary receptors driving tumor angiogenesis alongside FGFR1, FGFR2, FGFR3, and FGFR4, PDGFRα, RET, and KIT. This broad multi-kinase activity distinguishes lenvatinib from selective VEGFR inhibitors.

By blocking VEGFR signaling, lenvatinib disrupts the formation of new blood vessels that solid tumors depend on for oxygen and nutrients a process called tumor angiogenesis. Simultaneous blockade of FGFR1–4 prevents fibroblast growth factor (FGF) escape signaling, which is the primary mechanism by which tumors develop resistance to pure anti-VEGF therapies. Inhibition of RET kinase is clinically important in differentiated thyroid cancer, where RET/PTC rearrangements and RET mutations are common oncogenic drivers. Together, these actions reduce tumor vascularity, inhibit tumor cell proliferation, and suppress tumor metastasis. Oncologists managing patients across thyroid, liver, kidney, and endometrial malignancies can source Lenvaxen 4 MG and 10 MG (Lenvatinib) alongside a complete range of targeted therapies from the Mediaid Pharmacy oncology medicines catalogue.

In the SELECT phase III trial for radioiodine-refractory differentiated thyroid cancer, lenvatinib 24 mg once daily achieved a median progression-free survival (PFS) of 18.3 months versus 3.6 months on placebo (hazard ratio 0.21, p<0.0001), representing an 80% reduction in the risk of progression or death. In the REFLECT trial for hepatocellular carcinoma, lenvatinib produced a superior median PFS of 7.4 months versus 3.7 months for sorafenib, establishing lenvatinib as a first-line standard of care in HCC.

Approved Indications of Lenvatinib (Reference Label for Lenvaxen 4 MG and 10 MG)

Lenvatinib, the active ingredient in Lenvaxen 4 MG and 10 MG, is approved internationally in the following adult oncology indications. Prescribers should confirm the exact approved indications on the product label supplied with their import.

Radioiodine-Refractory Differentiated Thyroid Cancer (DTC)

Lenvatinib 24 mg once daily is approved for adults with progressive, radioactive iodine (RAI)-refractory locally recurrent or metastatic, well-differentiated follicular, papillary, or poorly differentiated thyroid cancer. In the SELECT trial, lenvatinib extended median PFS from 3.6 months (placebo) to 18.3 months (HR 0.21, p<0.0001). The standard 24 mg dose is achieved by combining 4 mg and 10 mg Lenvaxen capsules.

Unresectable Hepatocellular Carcinoma (HCC) First-Line

Lenvatinib is approved as a first-line treatment for adults with unresectable hepatocellular carcinoma. The REFLECT trial established non-inferiority to sorafenib in overall survival (median OS 13.6 vs 12.3 months) with a statistically superior PFS of 7.4 vs 3.7 months. Dosing is 12 mg once daily for patients weighing 60 kg or more, and 8 mg once daily for those weighing less than 60 kg.

Advanced Renal Cell Carcinoma (RCC) With Everolimus

Lenvatinib 18 mg once daily combined with everolimus 5 mg once daily is approved for adults with advanced renal cell carcinoma following one prior anti-angiogenic therapy. In Study 205, the lenvatinib plus everolimus combination achieved a median PFS of 14.6 months versus 5.5 months for everolimus alone a 63% reduction in the risk of progression.

Advanced Endometrial Carcinoma With Pembrolizumab

Lenvatinib 20 mg once daily combined with pembrolizumab 200 mg intravenously every 3 weeks is approved for adults with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), following prior systemic therapy. In the KEYNOTE-775 trial, this combination extended median PFS to 7.2 months versus 3.8 months for chemotherapy.

Key Clinical Benefits of Lenvaxen 4 MG and 10 MG (Lenvatinib)

80% PFS Reduction in Thyroid Cancer (SELECT)

In the SELECT phase III trial, lenvatinib 24 mg once daily reduced the risk of disease progression or death by 80% versus placebo (HR 0.21), extending median PFS from 3.6 to 18.3 months in radioiodine-refractory differentiated thyroid cancer.

Superior PFS Over Sorafenib in Liver Cancer (REFLECT)

In the REFLECT trial for unresectable HCC, lenvatinib produced a significantly superior median PFS of 7.4 months versus 3.7 months for sorafenib, positioning Lenvaxen 4 MG and 10 MG as a preferred first-line oral option for hepatocellular carcinoma.

Oral Capsule No Injections or Infusions Required

Lenvaxen 4 MG and 10 MG is a capsule taken by mouth once daily, enabling outpatient treatment without hospital infusion visits. The two-strength capsule design allows precise dose titration for each oncology indication under specialist supervision.

Tripling PFS in Renal Cell Carcinoma (Study 205)

Lenvatinib plus everolimus achieved a median PFS of 14.6 months versus 5.5 months for everolimus alone in advanced RCC after prior anti-angiogenic therapy a more than 2.6-fold improvement in time to progression in Study 205.

Durable Benefit in Endometrial Carcinoma (KEYNOTE-775)

In KEYNOTE-775, lenvatinib combined with pembrolizumab nearly doubled median PFS (7.2 vs 3.8 months) versus chemotherapy in previously treated advanced endometrial carcinoma, providing clinically meaningful progression-free benefit across a challenging tumor type.

Export Supply From Mediaid Pharmacy

Lenvaxen 4 MG and 10 MG Lenvatinib is available for export in 30’s packs from Mediaid Pharmacy, with specialist ordering support, stock confirmation, and worldwide shipping for licensed importers, hospitals, and oncology distributors.

How to Take Lenvaxen 4 MG and 10 MG (Lenvatinib): Dosage Guidelines

Route of Administration: Oral. Swallow the capsule whole with water once daily at approximately the same time each day, with or without food. If a dose is missed and cannot be taken within 12 hours, skip that dose and resume the next scheduled dose. Do not take two doses on the same day.

Differentiated Thyroid Cancer (DTC): The reference label recommends 24 mg once daily. This dose is achieved by combining Lenvaxen capsules for example, two 10 mg capsules plus one 4 mg capsule as directed by the prescribing oncologist. First dose reduction is to 20 mg, second to 16 mg, third to 12 mg once daily.

Hepatocellular Carcinoma (HCC): The reference label recommends 12 mg once daily for patients weighing 60 kg or more, and 8 mg once daily for patients weighing less than 60 kg. First dose reduction for patients at 12 mg is to 8 mg; second reduction to 4 mg. First dose reduction for patients at 8 mg is to 4 mg; further reductions are not permitted.

Renal Cell Carcinoma (RCC) with Everolimus: The reference label recommends lenvatinib 18 mg once daily (one 10 mg + two 4 mg capsules) combined with everolimus 5 mg once daily. First dose reduction of lenvatinib is to 14 mg, second to 10 mg. Refer to the everolimus label for its dose modification guidance.

Endometrial Carcinoma with Pembrolizumab: The reference label recommends lenvatinib 20 mg once daily (two 10 mg capsules) combined with pembrolizumab 200 mg intravenously every 3 weeks. First dose reduction of lenvatinib is to 16 mg (one 10 mg + one 4 mg + one 2 mg… use available strengths per prescriber direction); second reduction to 12 mg; third to 8 mg.

Hepatic Impairment: No dose adjustment is required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment in DTC. For severe hepatic impairment (Child-Pugh C), the recommended DTC dose is 14 mg once daily. Prescribers should consult the full reference label for HCC-specific hepatic impairment guidance.

Renal Impairment: No dose adjustment is required for mild or moderate renal impairment. For severe renal impairment (creatinine clearance 15–29 mL/min), the recommended DTC dose is 14 mg once daily. Lenvatinib has not been studied in patients requiring dialysis. Always follow the prescribing physician’s instructions for dose modification.

Prescription Medication: Important Warnings for Hypertension, Cardiac Dysfunction, Arterial Thromboembolic Events, Hepatotoxicity, Renal Failure, GI Perforation/Fistula, QT Prolongation, Hypocalcemia, and Embryo-Fetal Toxicity. The reference label for lenvatinib carries important warnings for these serious risks. Lenvaxen 4 MG and 10 MG (Lenvatinib) must be used only under the supervision of a qualified oncologist experienced with targeted anti-cancer therapies. Always follow your prescribing physician’s instructions regarding dose modifications, monitoring, and management of adverse events.

Clinical Monitoring Requirements During Lenvaxen 4 MG and 10 MG (Lenvatinib) Treatment

Systematic monitoring is mandatory throughout lenvatinib treatment. Before starting therapy, clinicians confirm baseline blood pressure, liver function tests (AST, ALT, bilirubin), renal function (creatinine, eGFR), urinalysis for proteinuria, thyroid function (TSH), serum calcium, and a 12-lead electrocardiogram (ECG) for QTc interval. Lenvatinib is not recommended in patients with uncorrected QTc prolongation above 480 ms or with uncontrolled hypertension.

During treatment, oncologists monitor blood pressure weekly for the first two months, then monthly thereafter; hypertension is the most common adverse event, occurring in up to 73% of DTC patients in the SELECT trial. Proteinuria is assessed by urine dipstick at every clinical visit; 24-hour urine protein is measured when dipstick reads 2+ or higher. Liver function tests and renal function are rechecked every 2 weeks for the first 2 months, then monthly. Serum calcium is monitored at least monthly because hypocalcemia, including symptomatic and life-threatening events, has been reported. TSH is measured monthly in patients with thyroid cancer and every 6–12 weeks in other indications. Patients should avoid surgery while on lenvatinib; the drug is held for at least 1 week before elective surgery and resumed only after adequate wound healing.

Drug Interactions and Important Safety Information for Lenvaxen 4 MG and 10 MG (Lenvatinib)

Lenvatinib is metabolized primarily through CYP3A and by aldehyde oxidase and UGT1A1. Strong CYP3A4 inducers such as rifampin and carbamazepine may reduce lenvatinib plasma exposure, potentially lowering efficacy. Strong CYP3A4 inhibitors such as ketoconazole and itraconazole may increase lenvatinib exposure. Caution is required when lenvatinib is used alongside other agents known to prolong the QT/QTc interval, including certain anti-arrhythmics, antiemetics, and antimicrobials, because additive QT prolongation risk has been documented.

Patients must inform their oncologist about all prescription medicines, over-the-counter products, herbal supplements, and antihypertensive agents before starting Lenvaxen 4 MG and 10 MG. Women of reproductive potential must use effective contraception during treatment and for at least 30 days after the final dose. Breastfeeding is not recommended during treatment and for at least 1 week after the last dose due to the potential for serious adverse reactions in a breastfed infant. Male patients with female partners of reproductive potential should use contraception during treatment and for 1 week after the final dose.

Side Effects and Precautions of Lenvaxen 4 MG and 10 MG (Lenvatinib)

Common Side Effects

Hypertension (high blood pressure) most frequent, up to 73% in DTC trials

Fatigue and asthenia (weakness)

Diarrhea

Decreased appetite and weight loss

Nausea and vomiting

Stomatitis (mouth sores/mucositis)

Palmar-plantar erythrodysesthesia (hand-foot syndrome)

Proteinuria (protein in the urine)

Hypothyroidism (in non-thyroid cancer patients)

Headache, arthralgia, and myalgia

Serious Warnings and Precautions

Hypertensive crisis: blood pressure must be controlled before and during treatment; interrupt or discontinue if hypertension is severe or uncontrolled.

Hepatotoxicity: serious hepatic events including hepatic failure have occurred; monitor liver enzymes and hold or discontinue for severe hepatotoxicity.

Arterial thromboembolic events: myocardial infarction and cerebral infarction have been reported; discontinue for arterial thromboembolic events.

GI perforation and fistula: serious gastrointestinal perforations and fistulas, some fatal, have occurred; discontinue immediately.

QT prolongation: can prolong QT interval; monitor ECG and electrolytes; avoid use with other QT-prolonging agents.

Hypocalcemia: life-threatening events have been reported; monitor and correct serum calcium before and during treatment.

Embryo-fetal toxicity: lenvatinib can cause fetal harm; advise women of reproductive potential to use effective contraception during treatment and for 30 days after the final dose.

Who Should Use Lenvaxen 4 MG and 10 MG (Lenvatinib)?

Lenvaxen 4 MG and 10 MG (Lenvatinib) is prescribed for adults with progressive radioiodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma (first-line), advanced renal cell carcinoma after prior anti-angiogenic therapy (with everolimus), or advanced endometrial carcinoma not amenable to curative surgery or radiation and not MSI-H/dMMR (with pembrolizumab). Patients with uncontrolled hypertension, uncorrected QTc prolongation, severe hepatic impairment (for most indications), or a recent history of arterial thromboembolic events require careful oncologist evaluation before lenvatinib initiation. Lenvaxen 4 MG and 10 MG Lenvatinib is prescribed by oncologists and endocrinologists experienced with multi-kinase inhibitor therapy for solid tumors. Buyers who supply patients across multiple oncology needs can also source complementary targeted therapies from the Mediaid Pharmacy oncology specialty medicines range.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Lenvaxen 4 MG and 10 MG (Lenvatinib)

Mediaid Pharmacy is a Dhaka-based supplier of specialty and oncology medicines with worldwide shipping. Lenvaxen 4 MG and 10 MG (Lenvatinib) is available under an Export Only registration in a 30’s capsule pack, so orders are handled for importers, hospitals, oncology centers, and distributors in destination markets that hold the necessary import authorization. Our team provides pricing quotations, stock confirmation, documentation, and delivery tracking through WhatsApp, phone, or WeChat for all questions about Lenvaxen 4 MG and 10 MG Lenvatinib. Importers who require several oncology products in one consignment can review the complete oncology medicine collection and request a combined quotation.

Why Choose Lenvaxen 4 MG and 10 MG (Lenvatinib) from Mediaid Pharmacy?

Lenvaxen 4 MG and 10 MG (Lenvatinib) gives importers and oncology healthcare providers an export-supplied multi-kinase inhibitor capsule for thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma, backed by the clinical evidence from the SELECT, REFLECT, Study 205, and KEYNOTE-775 trials. Mediaid Pharmacy provides clear product specifications, direct specialist support, and worldwide shipping for every order, and each enquiry is handled as a prescription-based or licensed-buyer request. To source additional targeted oncology therapies, visit the Mediaid Pharmacy oncology medicines section, then contact our team for a personalized quotation.

Frequently Asked Questions About Lenvaxen 4 MG and 10 MG (Lenvatinib)

What is Lenvaxen 4 MG and 10 MG (Lenvatinib) used for?

Lenvaxen 4 MG and 10 MG (Lenvatinib) is an oral multi-kinase inhibitor capsule used in adults with radioiodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma (first-line), advanced renal cell carcinoma (in combination with everolimus), and advanced endometrial carcinoma (in combination with pembrolizumab). Lenvatinib works by simultaneously blocking VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT, cutting off tumor blood supply and suppressing tumor cell growth.

What is the generic name of Lenvaxen?

The generic name of Lenvaxen is lenvatinib. Lenvaxen is available as 4 mg and 10 mg capsules in a 30’s pack under an Export Only registration. The originator reference brand for lenvatinib is Lenvima, developed by Eisai and co-marketed with Merck for certain oncology indications.

What is the correct dose of Lenvaxen 4 MG and 10 MG (Lenvatinib)?

Your oncologist sets the dose based on your indication and body weight. The reference label recommends 24 mg once daily for radioiodine-refractory differentiated thyroid cancer, 12 mg once daily (≥60 kg) or 8 mg once daily (<60 kg) for hepatocellular carcinoma, 18 mg once daily with everolimus 5 mg for renal cell carcinoma, and 20 mg once daily with pembrolizumab for endometrial carcinoma. The two strengths 4 mg and 10 mg capsules allow precise dosing and dose reductions in steps of 4 mg. Never adjust your dose without medical guidance.

What strengths and pack sizes is Lenvaxen available in?

Lenvaxen is available as 4 mg and 10 mg capsules, both supplied in a 30’s pack (30 capsules per pack). Having both strengths enables flexible dosing for each oncology indication for example, two 10 mg plus one 4 mg capsule achieves the 24 mg thyroid cancer dose. Contact Mediaid Pharmacy for current stock availability and shipping details for your country.

What are the side effects of Lenvaxen 4 MG and 10 MG (Lenvatinib)?

Common side effects include hypertension (in up to 73% of thyroid cancer patients), fatigue, diarrhea, decreased appetite, weight loss, nausea, stomatitis, hand-foot syndrome, proteinuria, and hypothyroidism. Serious risks include hepatotoxicity, arterial thromboembolic events, hypertensive crisis, gastrointestinal perforation or fistula, QT prolongation, and hypocalcemia. Blood pressure, liver enzymes, renal function, calcium, and TSH are monitored throughout treatment. Discuss your individual risk profile with your oncologist before starting therapy.

What tests are needed before starting lenvatinib?

Physicians obtain a baseline blood pressure measurement, liver function tests (AST, ALT, bilirubin), renal function tests (creatinine, eGFR), urinalysis with spot urine protein-to-creatinine ratio, serum calcium, thyroid-stimulating hormone (TSH), and a 12-lead ECG for QTc interval before starting lenvatinib. Treatment is withheld until blood pressure is adequately controlled and QTc is not above 480 ms. These baseline assessments establish safe starting conditions and reference values for ongoing monitoring.

Is Lenvaxen 4 MG and 10 MG safe during pregnancy or while breastfeeding?

No. Lenvatinib can cause fetal harm and is not recommended during pregnancy, based on its mechanism of action and animal studies demonstrating embryo-fetal lethality and teratogenicity. Women of reproductive potential must use effective contraception during treatment and for at least 30 days after the final dose. Breastfeeding is not recommended during treatment and for at least 1 week after the final dose, because lenvatinib and its metabolites may be present in human milk. Male patients should also use contraception during treatment and for 1 week after the last dose when their partner could become pregnant.

What does an Export Only registration mean for Lenvaxen?

An Export Only registration means Lenvaxen is manufactured and registered for supply to international markets outside its country of origin, and it is not sold to patients in the domestic market where it is produced. Importers must hold the marketing authorization or import permit required by their own national drug regulatory authority before placing an order with Mediaid Pharmacy.

Can I order Lenvaxen 4 MG and 10 MG (Lenvatinib) online with worldwide shipping?

Yes, for eligible licensed importers, oncology hospitals, and registered healthcare distributors. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, stock availability, export documentation, and delivery details for your country.

Order Lenvaxen 4 MG and 10 MG (Lenvatinib) with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Message on WhatsApp

Related products